For instance, among patients with PD-L1-positive NSCLC (1% or more), atezolizumab 1200 mg every three weeks until disease progression or unacceptable toxicity has produced a response rate of 31% observed on CT scan at regular intervals. Here, CD274 is linked to non-small cell lung carcinoma.